

Analysis of Covariance (ANCOVA) of Change from Baseline in
Fasting Glucose (mmol/L) at Week 24 (LOCF)
Efficacy Analysis Population

| | Baseline | | Week 24 (LOCF) | | Change from Baseline | | |
|---|----------|------------|---|------------|----------------------|-------------|-------------------------------|
| Treatment Group | N | Mean (SD) | N | Mean (SD) | N | Mean (SD) | LS Mean (95% CI) ^a |
| Placebo | 79 | 5.7 (2.23) | 79 | 5.6 (1.65) | 79 | -0.0 (2.32) | 0.07 (-0.26, 0.41) |
| Xanomeline Low Dose | 79 | 5.4 (0.95) | 79 | 5.4 (1.06) | 79 | -0.1 (1.02) | -0.11 (-0.44, 0.23) |
| Xanomeline High Dose | 74 | 5.4 (1.37) | 74 | 5.8 (2.21) | 74 | 0.4 (1.65) | 0.39 (0.04, 0.74) |
| Pairwise Comparison | | | Difference in LS Mean (95% CI) ^a | | | | p-Value ^b |
| Xanomeline Low Dose vs. Placebo | | | -0.18 (-0.65, 0.30) | | | | 0.4670 |
| Xanomeline High Dose vs. Placebo | | | 0.32 (-0.17, 0.80) | | | | 0.2004 |
| ^a LS means and differences in LS means are based on an ANCOVA model with treatment and baseline glucose as covariates. | | | | | | | |
| ^b p-values are from the ANCOVA model testing treatment effects (overall F-test p-value: 0.0000). | | | | | | | |
| LOCF (Last Observation Carried Forward) approach is used for missing Week 24 values. | | | | | | | |
| ANCOVA = Analysis of Covariance; CI = Confidence Interval; LS = Least Squares; SD = Standard Deviation | | | | | | | |

Source: ADLBC Analysis Dataset
Analysis conducted: 06NOV2025
Statistical software: Python (statsmodels)